Nebula Research & Development LLC Buys 7,871 Shares of Cabot Co. (NYSE:CBT)

Nebula Research & Development LLC raised its stake in shares of Cabot Co. (NYSE:CBT - Free Report) by 85.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,134 shares of the specialty chemicals company's stock after purchasing an additional 7,871 shares during the quarter. Nebula Research & Development LLC's holdings in Cabot were worth $1,565,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in CBT. Norges Bank purchased a new position in Cabot in the fourth quarter worth $37,961,000. Copeland Capital Management LLC boosted its holdings in shares of Cabot by 21.6% in the 4th quarter. Copeland Capital Management LLC now owns 761,372 shares of the specialty chemicals company's stock worth $69,521,000 after purchasing an additional 135,119 shares in the last quarter. American Century Companies Inc. increased its position in shares of Cabot by 8.5% during the 4th quarter. American Century Companies Inc. now owns 1,323,347 shares of the specialty chemicals company's stock valued at $120,835,000 after purchasing an additional 103,380 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Cabot by 27.1% in the 4th quarter. JPMorgan Chase & Co. now owns 451,513 shares of the specialty chemicals company's stock worth $41,228,000 after buying an additional 96,179 shares during the last quarter. Finally, Marshall Wace LLP raised its stake in shares of Cabot by 3,242.5% during the fourth quarter. Marshall Wace LLP now owns 74,338 shares of the specialty chemicals company's stock worth $6,788,000 after acquiring an additional 72,114 shares in the last quarter. Institutional investors own 93.18% of the company's stock.

Analyst Upgrades and Downgrades

CBT has been the topic of several recent analyst reports. StockNews.com raised Cabot from a "hold" rating to a "buy" rating in a research note on Thursday, April 17th. Mizuho cut their price objective on Cabot from $122.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. JPMorgan Chase & Co. decreased their target price on Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a report on Friday, February 21st. Finally, UBS Group reduced their price objective on shares of Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th.

Cabot Stock Down 1.4 %

Shares of NYSE:CBT traded down $1.12 during trading on Thursday, hitting $77.42. The stock had a trading volume of 209,982 shares, compared to its average volume of 392,680. The company has a market capitalization of $4.20 billion, a PE ratio of 10.28, a PEG ratio of 0.74 and a beta of 1.04. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72. The firm's fifty day moving average is $81.48 and its 200 day moving average is $93.14. Cabot Co. has a 12 month low of $73.63 and a 12 month high of $117.46.

Cabot (NYSE:CBT - Get Free Report) last announced its quarterly earnings data on Monday, February 3rd. The specialty chemicals company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. Analysts anticipate that Cabot Co. will post 7.57 EPS for the current fiscal year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.